PA
KYMR icon

Perceptive Advisors’s Kymera Therapeutics KYMR Stock Holding History

Perceptive Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-69,935
Closed -$5.44M – 117
2025
Q4 		$5.44M Sell
69,935
-99,861
-59% -$6.74M 0.1% 89
2025
Q3 		$9.61M Sell
169,796
-40,310
-19% -$1.82M 0.28% 59
2025
Q2 		$9.17M Buy
+210,106
New +$7.23M 0.34% 54
2024
Q4 		– Sell
-46,213
Closed -$2.19M – 111
2024
Q3 		$2.19M Buy
+46,213
New +$2.04M 0.05% 93
2022
Q1 		– Sell
-155,000
Closed -$9.84M – 146
2021
Q4 		$9.84M Sell
155,000
-25,000
-14% -$1.46M 0.15% 95
2021
Q3 		$10.6M Buy
+180,000
New +$10.4M 0.15% 98

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors's KYMR Position: Q1 2026 in Review

Perceptive Advisors sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 69,935 shares — an estimated $5.44M sold.

Perceptive Advisors first reported a position in KYMR in Q3 2021 and held it in 6 quarters. The position peaked at $10.6M in Q3 2021. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Perceptive Advisors reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Perceptive Advisors sold 69,935 Kymera Therapeutics shares in Q1 2026, an estimated $5.44M.
  • Perceptive Advisors first reported a position in Kymera Therapeutics in Q3 2021 and held it in 6 quarters.
  • Perceptive Advisors's Kymera Therapeutics position peaked at $10.6M in Q3 2021.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.